The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Name:	us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Asset Acquisition and License Agreements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Dec. 31, 2015	Jun. 30, 2019	Jun. 30, 2019
Asset Acquisition [Line Items]
Impairment charge of intangible asset			$ 3,151
SRX Cardio
Asset Acquisition [Line Items]
Variable interest entity, Upfront payment	$ 500
Gain on de-recognition of contingent milestone payable		$ 2,300	2,300
SRX Cardio \| In-process Research and Development
Asset Acquisition [Line Items]
Impairment charge of intangible asset		$ 3,200	$ 3,200